Skip to content
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
Icône L&M 2L&M 2
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact
Icône L&M 3L&M 3
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
Icône L&M 2L&M 2
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact
Icône L&M 3L&M 3
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact

Tag: Lm1 2023 theme knowledge

Lm1 theme knowledge 2023

LM N°1 / 2023. What's new in the drug treatment of obesity? Ali Al-SHALEEL, MD, Jad BISSAR, MD, Barbara HERSANT, MD PHD.

What's new in the drug treatment of obesity? Ali Al-SHALEEL, Jad BISSAR, Barbara HERSANT, MD PHD. Place des MAO (Médicaments Anti-obésité) INTRODUCTION Obesity is recognized as a major pandemic of the 21st century, contributing to increased morbidity, mortality and healthcare cost burden. Overweight and obesity are [...]

LM N°1/2020. Subjects still taboo. Video presentation : " Vaginal rejuvenation with DESIRIAL PLUS " . By VIVACY

  • TO BE A LEADER IN ANTI-AGING MEDICINE
  • QUALITY COMMUNICATION 
  • INNOVATIVE VISUAL OFFERS
  • STRONG DIGITAL COMMUNICATION FOR MANUFACTURERS
  • AN ORIGINAL AND SCIENTIFIC MULTIMEDIA EXPERTISE
  • THE L&M BRAND: A REFERENCE FOR AESTHETIC HEALTH PROFESSIONALS

Useful links

  • Contact
  • CGU
  • Blog

Social networks

Instagram Facebook-f

Website and mobile application designed by CAPROVE